$1.22
+0.03 (+2.52%)
Open$1.20
Previous Close$1.19
Day High$1.27
Day Low$1.18
52W High$2.98
52W Low$1.03
Volume—
Avg Volume1.80M
Market Cap100.37M
P/E Ratio—
EPS$-1.70
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+1,507.4% upside
Current
$1.22
$1.22
Target
$19.61
$19.61
$14.26
$19.61 avg
$29.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 115.2K | 621.6K | 29.02M |
| Net Income | -149,054,415 | -723,955,604 | -227,719 |
| Profit Margin | -130,006.0% | -123,505.7% | -0.8% |
| EBITDA | -149,860,693 | -768,309,003 | -290,155 |
| Free Cash Flow | — | — | -255,634 |
| Rev Growth | -81.5% | -81.5% | +16.9% |
| Debt/Equity | — | — | 0.72 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |